These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2469333)

  • 1. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma.
    Hedrick L; Epstein JI
    Am J Surg Pathol; 1989 May; 13(5):389-96. PubMed ID: 2469333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
    Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
    Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.
    Wojno KJ; Epstein JI
    Am J Surg Pathol; 1995 Mar; 19(3):251-60. PubMed ID: 7532918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies.
    Abrahams NA; Ormsby AH; Brainard J
    Histopathology; 2002 Jul; 41(1):35-41. PubMed ID: 12121235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates.
    Brawer MK; Nagle RB; Pitts W; Freiha F; Gamble SL
    Cancer; 1989 Feb; 63(3):454-60. PubMed ID: 2463873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
    Chen YB; Fine SW; Epstein JI
    Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia.
    Maygarden SJ; Strom S; Ware JL
    Arch Pathol Lab Med; 1992 Mar; 116(3):269-73. PubMed ID: 1371380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of triple antibody (34βE12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins.
    Daoud NA; Li G; Evans AJ; van der Kwast TH
    J Clin Pathol; 2012 May; 65(5):437-40. PubMed ID: 22294716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
    Epstein JI
    Mod Pathol; 2004 Mar; 17(3):307-15. PubMed ID: 14739905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of high-molecular-weight cytokeratin antigenicity in prostate tissue obtained by transurethral resections.
    Multhaupt HA; Fessler JN; Warhol MJ
    Arch Pathol Lab Med; 2000 Dec; 124(12):1764-7. PubMed ID: 11100054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunohistochemical analysis with anti-cytokeratin antibody in the prostatic epithelium].
    Yamanaka Y; Ishida H; Okada K; Nemoto N
    Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):545-53. PubMed ID: 11517564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative 34betaE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases.
    Halushka MK; Kahane H; Epstein JI
    Hum Pathol; 2004 Jan; 35(1):43-6. PubMed ID: 14745723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate.
    Shah IA; Schlageter MO; Stinnett P; Lechago J
    Mod Pathol; 1991 Mar; 4(2):220-4. PubMed ID: 1710806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of prostate carcinoma on biopsy specimens improved by basal-cell-specific anti-cytokeratin antibody (34 beta E12).
    Freibauer C
    Wien Klin Wochenschr; 1998 Sep; 110(17):608-11. PubMed ID: 9816630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns.
    Yaskiv O; Cao D; Humphrey PA
    Am J Surg Pathol; 2010 Apr; 34(4):556-61. PubMed ID: 20216381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens.
    Kaleem Z; Swanson PE; Vollmer RT; Humphrey PA
    Am J Clin Pathol; 1998 Jun; 109(6):695-703. PubMed ID: 9620026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucin expression in atypical adenomatous hyperplasia of the prostate.
    Goldstein NS; Qian J; Bostwick DG
    Hum Pathol; 1995 Aug; 26(8):887-91. PubMed ID: 7543443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy.
    Coogan CL; Bostwick DG; Bloom KJ; Gould VE
    Urology; 2003 Jan; 61(1):248-52. PubMed ID: 12559317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
    Weinstein MH; Signoretti S; Loda M
    Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
    Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
    Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.